Lack of the expression of EBNA-2 and LMP-1 in T-cell neoplasms possessing Epstein-Barr virus.
We investigated 34 cases of T-cell neoplasm [15 cases of T-cell granular lymphocytic leukemia (T-GLL), 10 cases of T-cell non-Hodgkin's lymphoma (T-NHL), six cases of T-cell chronic lymphocytic leukemia (T-CLL), and three cases of cutaneous T-cell lymphoma] to study their association with Epstein-Barr virus (EBV). In 4 (three T-NHL and one T-GLL) of 34 cases, EBV genome was detected in a single episomal form, while polyclonal EBV-DNA was detected in one (T-NHL) of the remaining cases. All three cases of T-NHL having monoclonal EBV episome showed histologically diffuse large-cell lymphoma and developed leukemic conversion. Phenotypic analysis showed that two of these four cases were CD4+, CD8-, and the remaining two cases were CD4-, CD8+. The cells from all four cases were confirmed to be in T-cell lineage by detecting the rearrangement of T-cell receptor (TCR) beta or gamma chain gene. By reverse transcription-polymerase chain reaction (RT-PCR), EBNA-1 was detected at low levels, and neither EBNA-2 nor LMP-1 were found in any of the three cases examined. Lack of the expression of EBNA-2 and LMP-1 was also confirmed by immunocytochemical staining. The cells of these four cases did not show rearrangement or overexpression of c-myc and bcl-2 genes by Southern and Northern blots, and the mutation of p53 gene was detected in only one patient. These results suggest that other latent gene products of EBV or other cellular oncogenes are involved in the development of Japanese T-cell neoplasm after EBV infection.
Suzushima
H
H
Second Department of Internal Medicine, Kumamoto University School of Medicine, Japan.
Asou
N
N
Fujimoto
T
T
Nishimura
S
S
Okubo
T
T
Yamasaki
H
H
Osato
M
M
Matsuoka
M
M
Tsukamoto
A
A
Takai
K
K
D000956:Antigens, Viral / Q000096:biosynthesis* / Q000235:genetics; D001483:Base Sequence; D004279:DNA, Viral / Q000032:analysis; D004268:DNA-Binding Proteins / Q000096:biosynthesis* / Q000235:genetics; D019309:Epstein-Barr Virus Nuclear Antigens; D015973:Gene Expression Regulation, Leukemic; D015967:Gene Expression Regulation, Viral; D016259:Genes, myc; D016158:Genes, p53; D006566:Herpesviridae Infections / Q000235:genetics*; D004854:Herpesvirus 4, Human / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D015461:Leukemia, Prolymphocytic, T-Cell / Q000235:genetics / Q000821:virology; D015458:Leukemia, T-Cell / Q000235:genetics / Q000821:virology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000821:virology; D016399:Lymphoma, T-Cell / Q000235:genetics / Q000821:virology*; D016410:Lymphoma, T-Cell, Cutaneous / Q000235:genetics / Q000821:virology; D008969:Molecular Sequence Data; D010957:Plasmids / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics; D019253:Proto-Oncogene Proteins c-bcl-2; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics; D014412:Tumor Virus Infections / Q000235:genetics*
D000956:Antigens, Viral; D004279:DNA, Viral; D004268:DNA-Binding Proteins; D019309:Epstein-Barr Virus Nuclear Antigens; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016693:Receptors, Antigen, T-Cell, alpha-beta